Education
About Us
Working with TipRanks
Follow Us
Algernon Pharmaceuticals (AGNPF)
OTHER OTC:AGNPF
AGNPF Stock Chart & Stats
$0.06
$0.00(0.00%)
At close: 4:00 PM EST
$0.06
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.04 - $0.09
Previous CloseN/A
Volume93.00
Average Volume (3M)7.73K
Market Cap
$2.12M
Enterprise Value$2.24M
Total Cash (Recent Filing)$88.18K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Dec 22, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding34,256,218
10 Day Avg. Volume2,484
30 Day Avg. Volume7,733
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.97
Price to Sales (P/S)0.00
P/FCF Ratio-0.75
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-87.26
Enterprise Value/Ebitda-1.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Algernon Pharmaceuticals News
AGNPF FAQ
What was Algernon Pharmaceuticals’s price range in the past 12 months?
Algernon Pharmaceuticals lowest stock price was $0.04 and its highest was $0.09 in the past 12 months.
What is Algernon Pharmaceuticals’s market cap?
Algernon Pharmaceuticals’s market cap is $2.12M.
When is Algernon Pharmaceuticals’s upcoming earnings report date?
Algernon Pharmaceuticals’s upcoming earnings report date is Dec 22, 2025 which is in 6 days.
How were Algernon Pharmaceuticals’s earnings last quarter?
Algernon Pharmaceuticals released its earnings results on Jul 30, 2025. The company reported -$0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.014.
Is Algernon Pharmaceuticals overvalued?
According to Wall Street analysts Algernon Pharmaceuticals’s price is currently Overvalued.
Does Algernon Pharmaceuticals pay dividends?
Algernon Pharmaceuticals does not currently pay dividends.
What is Algernon Pharmaceuticals’s EPS estimate?
Algernon Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Algernon Pharmaceuticals have?
Algernon Pharmaceuticals has 34,256,218 shares outstanding.
What happened to Algernon Pharmaceuticals’s price movement after its last earnings report?
Algernon Pharmaceuticals reported an EPS of -$0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Algernon Pharmaceuticals?
Currently, no hedge funds are holding shares in AGNPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Algernon Pharmaceuticals
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---